CEO and Founder of Invetx with the vision for Invetx to become the leading veterinary biotherapeutics company.15+ years in various leadership roles in Marketing and R&D in the Animal Health industry and biotech. New product development for glo

Jonathan Solomon, BiomX - Part of the Nametag Series

Dec 15th, 2020 33m 57s

Prior to his role in BiomX, Mr. Solomon was a co-founder, president, and CEO of ProClara (formerly NeuroPhage), which is pioneering an approach to treating neurodegenerative diseases. Under his leadership, the company raised more than $100 mill

Jonathan Drachman, Neoleukin Therapeutics - Part of the Nametag Series

Dec 14th, 2020 43m 47s

Jonathan is a seasoned clinician, researcher, and biopharmaceutical executive who joined Neoleukin at the company’s founding in 2018. For 14 years prior, he was at Seattle Genetics, where he most recently served as Chief Medical Officer and Exe

Dale Chappell, Humanigen - Part of the Nametag Series

Dec 14th, 2020 24m 48s

- Founder, Black Horse Capital Advisors- Decades of biotechnology investment experience- HHMI Fellow, National Cancer Institute, Rosenberg Lab- Multiple publications in T-cell therapy, GM-CSF and immunology pathways

Brandi Roberts, Lineage Cell Therapeutics - Part of the Nametag Series

Dec 3rd, 2020 24m 26s

Ms. Roberts joined Lineage as Chief Financial Officer in January 2019. Prior to joining Lineage, Ms. Roberts served from August 2017 to January 2019 as Chief Financial Officer at REVA Medical, Inc. Ms. Roberts previously served as Chief Financi

Richard Godfrey, BerGenBio - Part of the NameTag Series - Update

Nov 30th, 2020 35m 13s

Richard Godfrey joined BerGenBio as Chief Executive Officer in 2008. He has more than 25 years' industry experience leading many international drug development and commercialisation partnerships. Formerly he served as Chief Executive Officer of

Pawel Przewiezlikowski, Ryvu - Part of the Name Tag Series

Nov 24th, 2020 21m 45s

Mr. Przewiezlikowski is the Chief Executive Officer and founder of Ryvu Therapeutics, responsible for strategic management, business and corporate development of the company. He is also the President of Supervisory Board at Ardigen and Member o

David Parkinson, ESSA Pharma - Part of the Name Tag Series

Nov 20th, 2020 32m 2s

Dr. Parkinson has served as President and Chief Executive Officer of ESSA Pharma Inc. since January 2016, and as a Director of the company since June 2015. Prior to joining ESSA he had been a Venture Partner at New Enterprise Associates, Inc. F

Lucy Lu, Kintor Pharmaceutical - Part of the Name Tag Series

Nov 19th, 2020 22m 16s

Over 13 years of experience in investment banking businessFormer Director and Managing Director of GF Capital (Hong Kong)Former executive director of UBS Hong Kong in Asia healthcare groupObtained the sponsor license of Hong Kong listing in

Srinivas Rao, ATAI Life Sciences - Part of the Name Tag Series

Sep 14th, 2020 26m 22s

Srinivas Rao is the Chief Scientific Officer at ATAI Life Sciences AG. Dr. has over 19 years of professional experience in the pharmaceutical and biotechnology industries. Prior to ATAI, Dr. Rao has held the titles of Chief Scientific, Medical,

David Main, Notch Therapeutics - Part of the Name Tag Series

Aug 28th, 2020 22m 25s

David Main is President and Chief Executive Officer of Notch Therapeutics. Previously, as Chairman and CEO of Aquinox Pharmaceuticals, a company he founded in 2004, Mr. Main oversaw the advancement of the company’s lead product from target vali

Brian Culley, Lineage Cell Therapeutics - Part of the TimeStamp Series

Aug 19th, 2020 32m

Mr. Culley joined Lineage as CEO in September 2018. Prior to joining Lineage, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he was responsible for the manage

Rob de Ree, NorthSea - Part of the NameTag Series

Aug 18th, 2020 30m 57s

Prior to joining NorthSea Therapeutics B.V., Rob de Ree served as the CEO of the start-up companies Dezima Pharma, which was acquired by Amgen in 2015 and as the CEO of BMEYE which was acquired by Edwards lifesciences in 2012. Before that Rob d

Theresa Heah, Asclepix - Part of the Name Tag Series

Aug 12th, 2020 25m 50s

Prior to joining AsclepiX Therapeutics, Dr. Heah served as Chief Medical Officer at Applied Genetic Technologies Corporation (AGTC), where she worked on developing ophthalmic gene therapies. Before her tenure at AGTC, Dr. Heah was Vice Presiden

Niquette Hunt, Candesant - Part of the NameTag Series

Aug 6th, 2020 23m 52s

Niqui has over 25 years experience in developing, launching and commercially scaling 20+ products in both large corporations (P&G, Warner Lambert) and early stage companies across multiple verticals in the consumer medicine market. Every busin

Alex Zapesochny, Clerio Vision - Part of the NameTag Series

Aug 4th, 2020 33m 45s

Alex is an experienced technology executive and attorney who previously served as Executive Vice President of Cardiac Safety at ERT.A co-founder of iCardiac Technologies, Alex served as its President and CEO until ERT acquired the company in

Vishal Doshi, AUM Biosciences - Part of the NameTag Series

Aug 4th, 2020 35m 18s

Extensive experience in structuring and managing risk sharing deals in various roles worth over $1 billion USD.Extensive experience in clinical research across the pharmaceutical and CRO industry, spanning US, Europe and Asia.Key Opinion Lead

Bob Geho, Diasome - Part of the NameTag Series

Aug 3rd, 2020 45m 36s

Mr. Geho has twenty-five years of experience in the field of diabetes drug development and is a recognized leader in the industry’s effort to develop novel insulin therapies for people with Type 1 and Type 2 diabetes. As a patient-entrepreneur

Zach Hornby, Boundless Bio - Part of the NameTag Series

Jul 31st, 2020 21m 41s

Zachary (“Zach”) Hornby has served in executive and director roles for multiple private and public biotechnology companies. Prior to joining Boundless Bio, Zach was Chief Executive Officer, President and a Director at Optera Therapeutics Corp,

Bill Enright, Vaccitech - Part of the NameTag Series

Jul 30th, 2020 34m 55s

William “Bill” Enright is a seasoned biotech executive with more than thirty years of experience in building and financing both privately held and publicly held companies. Bill spent more than ten years at Altimmune (NASDAQ: ALT) as a Director,

Richard Andrews, Azitra - Part of the NameTag Series

Jul 30th, 2020 38m 10s

Mr. Andrews has spent most of his career as a C level executive leading operations, finance, and commercial and clinical development for biotechnology firms focused on new products that address inflammatory disease. Mr. Andrews has been instrum

Takashi Kei Kishimoto, Selecta Bio - Part of the NameTag Series

May 28th, 2020 35m 34s

Prior to joining Selecta Biosciences in 2011, Dr. Kishimoto was Vice President of Discovery Research at Momenta Pharmaceuticals, where he served in several leadership positions over the course of 5 years and led a multidisciplinary research gro

Melissa Epperly, Zentalis - Part of the NameTag Series

May 14th, 2020 20m 15s

Melissa is Chief Financial Officer at Zentalis Pharmaceuticals. She brings extensive experience as a senior financial executive in the life sciences industry. She most recently served as CFO at PsiOxus Therapeutics, a clinical-stage gene therap

Richard Godfrey, BerGenBio - Part of the NameTag Series

May 6th, 2020 23m 41s

Gerben Moolhuizen, ISA Pharmaceuticals - Part of the NameTag Series

Mar 16th, 2020 19m 21s

Gerben Moolhuizen has over twenty years of experience in the pharmaceutical and biotechnology industry in various roles covering business development, product development and general management. Prior to ISA Pharmaceuticals, he worked at OctoPl